Trials / Completed

CompletedNCT04917861

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 808 (actual)

Sponsor: ModernaTX, Inc. · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Accepted

Summary

This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.

Conditions

Zika Virus

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1893	Solution for injection
BIOLOGICAL	Placebo	0.9% sodium chloride solution for injection

Timeline

Start date: 2021-06-07
Primary completion: 2024-07-26
Completion: 2024-07-26
First posted: 2021-06-08
Last updated: 2025-09-25
Results posted: 2025-09-25

Locations

11 sites across 2 countries: United States, Puerto Rico

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04917861. Inclusion in this directory is not an endorsement.